Samenvatting
Terwijl onderzoek naar de mogelijkheden van ziektemodulerende medicatie bij dementie een boeiende ontwikkeling doormaakt, is de aandacht in de huidige klinische praktijk toch nog vooral gericht op symptoombestrijding. De behandeling van probleemgedrag speelt daarin een hoofdrol. De wetenschappelijke, evidence based (EBM), literatuur over analyse en behandeling van probleemgedrag is echter beperkt en het ontbreekt dan ook aan breder inzetbare richtlijnen.
Om hierin verandering te brengen werd door een werkgroep van ervaren specialisten uit verschillende disciplines een eerste praktisch bruikbare leidraad ontworpen op basis van beschikbare EBM-gegevens, voor medicamenteuze behandeling van agitatie en agressie bij dementie. Uitgangspunt daarbij is dat agitatie en agressie uitingen zijn van distress (uitgedrukt in het concept BPSD: ‘behavioral and psychological symptoms in dementia’) en een daarop gerichte analyse vereisen. Pas als niet-medicamenteuze maatregelen ter vermijding van distress falen kan in acute of niet-acute situaties medicamenteuze behandeling gewenst zijn. Er zijn maar weinig middelen die daarbij de toets der kritiek kunnen doorstaan en/of breed toepasbaar zijn. Vervolgens vereist de toepassing van medicatie een nauwgezette monitoring van het effect. De doelstelling van ons algoritme is vooral ook gestructureerde ervaring op te doen met medicamenteuze behandeling van agitatie en agressie bij dementie en verder wetenschappelijk onderzoek naar analyse en behandeling van BPSD te stimuleren.
Literatuur
Ackerknecht EH. Voorwoord. In: Esquirol JED. Geestesziekten. Uitgeverij Candide, Amsterdam 1993.
Aalten P, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium. Part I. Dementia and Geriatric Cognitive Disorders. 2007;24:457–463.
Gauthier S, et al. Management of behavioural problems in Alzheimer’s disease. Int Psychogeriatrics 2010;22(3):346–372.
Olde Rikkert MGM, Lemstra EW, Verhey FRJ. Te kleine rol voor tweede lijn in NHG-standaard ‘Dementie’. Ned T Geneeskunde 2012;156:A5554.
KNMG. Antipsychotica bij probleemgedrag bij dementia in verpleeg- en verzorgingshuis. GeBu 2013;47:27–33.
Kat M. The neuropsychiatry of dementia. Psychometrics, clinical implications and outcome. Thesis. Amsterdam 2009.
Cohen-Mansfield J, Libin A, Marx MS. Non-pharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol 2007;62A(8):908–916.
Ballard CG, et al. Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology 2009;5:245–255.
Verenso (NVVA). Richtlijn probleemgedrag. Beroepsvereniging van verpleeghuisartsen en sociaal geriaters. 2008.
Engelborghs S, et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriat Psychiatry 2005;20:1028–1037.
Schreinzer D, et al. Components of behavioural pathology in dementia. Int J Geriat Psychiatry 2005;20:137–145.
Aalten P, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008;25:1–8.
Savva GM, et al. 2009. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Brit J Psychiat 194:212–219.
Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. The Lancet 1997;349:1546–1549.
Van der Mussele S, et al. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer’s disease and healthy older adults. Int J Geriatr Psychiatry 2013;28:265–275.
Cummings JL. The neuropsychiatry of Alzheimer’s disease and relate dementias. London 2003. Martin Dunitz.
Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005;128:2612–2625.
Kaye ED, et al. Frontotemporal Dementia and Pharmacologic Interventions. The J Neuropsychiat Clin Neurosci 2010;22:19–29.
Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans RTCM. Environmental correlates of neuropsychiatric symptoms in Dutch nursing home patients with dementia. Int J Geriatr Psychiatry 2010;25:14–22.
Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans RTC. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behaviour. Int Psychogeriatrics 2011;23(10):1632–1639.
Ballenger JF. Self, senility, and Alzheimer’s disease in modern America. A History. John Hopkins University Press, Baltimore 2006.
Zuidema SU. Neuropsychiatric symptoms in Dutch nursing home patients with dementia. Thesis. Nijmegen 2007.
Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. In J Geriatr Psychiat 2004;19:881–891.
Reisberg B, Borenstein J, Salob S, Ferris SH, Franssen E. Behavioural symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987;48:9–15.
Cummings JL, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2380–2314.
De Jonghe JFM, Kat MG, Kalisvaart CJ, Boelaarts L. Neuropsychiatric inventory questionnaire (NPIQ): A validity study of the Dutch form. T Gerontol Geriatr 2003;34(2):74–77.
De Jonghe JFM. Factor structure and validity of the Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D). J Am Geriatr Soc 1996;44(7):888–889.
Cohen-Mansfield, J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361–381.
Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996–2021.
O’Connor DW, Ames D, Gardner B, King M. Psychological treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatrics 2009;21(2):241–251.
Zuidema SU. Probleemgedrag bij ouderen met dementie. T Ouderengeneeskunde 2010;5:187–193.
Hensiek AE, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry 2002;72:281–285.
Rochon PA, et al. Antipsychotic therapy and shortterm serious events in older adults with dementia. Arch Intern Med 2008;168(10):1090–1096.
Zuidema SU, van Iersel MB, Koopmans RTCM, Verhey FRJ, Olde Rikkert MGM. Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review. Ned Tijdschr Geneesk 2006;150:1565-1573.
Allen MH. Managing the agitated psychotic patient: a reappraisal of evidence. J Clin Psychiatry1 2000;61:Suppl 14:11–20.
Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65(9):1207–1222.
Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Br J Psychiatry 2004;185:63–69.
Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews 2006, Issue 1.
Hanagasi HA, Emre M. Treatment of behavioural symptoms and dementia in Parkinson’s disease. Fundamentals & Clinical Pharmacology 2005;19(2):33–146.
Cahn W, et al. (2008) Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. T v Psychiatrie 50(9):579–591.
Devanand DP. et al. Relapse risk after discontinuation of risperidon in Alzheimer’s disease. NEJM 2012;367:1497–1507.
Seitz DP, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews 2011, Issue 2.
Vieweg WV, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012;125(9):859–868.
Lanctot KL, et al. Central serotonergic activity is related to aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology 2002;27:646–654.
Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66:17–22.
Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: on movement, mood, and madness. Movement Disorders 2009;24(9):1255–1266.
Sultzer DL, et al. A double blind comparison of trazodon and haloperidol for the treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;7:60–69.
Rolanski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy Bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. The Cochrane Library. 2012
Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization and cholinesterase inhibitor treatment. The Gerontologist 2010;51:17–27.
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, et al. (2012) Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial. PLoS ONE 7(5): e35185.
Gauthier S, Loft H, Cummings J. Improvement of behavioural symptoms in patients with moderate tot severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23(5):537–545.
Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease. A pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341–348.
Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer’s disease. Int J Geriatr Psychiat 2011;27(8):769–76.
Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969–977.
Swanberg MM. Memantine for behavioural disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007;21(2):164–166.
Boxer AL, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12(2):149–156.
Tamblyn R, Abrahamowicz M, Berger R du, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53(2):233–241.
Author information
Authors and Affiliations
Corresponding author
Additional information
namens het Dementieplatvorm Zuid
Rights and permissions
About this article
Cite this article
van Domburg, D.P., Vromen, M., Collet, J. et al. Agitatie en agressie bij dementie: ontwerp van een evidence-based algoritme voor medicamenteuze behandeling. Tijdsvoor Neuropsy en Gedragsneuro 1, 36–44 (2013). https://doi.org/10.1007/s40533-013-0009-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40533-013-0009-3